Schizophrenia: Treatment Targets Beyond Monoamine Systems
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
We develop the proposal in this review that schizophrenia is a syndrome made up of component symptom complexes, each with distinctive clinical correlates, pathophysiology, and selective treatments. Psychosis is the necessary component of the syndrome; it has a young-adult onset and is sensitive to current antipsychotic drugs. Cognitive dysfunction often precedes psychosis onset, does not present an episodic course, and is poorly responsive to antipsychotic drugs. Treatments for cognition are being developed largely on the basis of animal pharmacology. Drugs for component symptom complexes will theoretically be coadministered to independent symptomatic end points. Animal models, some with genetic characteristics, can be more easily and directly developed to match an individual component than to match an illness definition as broad as schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia
Walsh, T., McClellan, J. M., McCarthy, S. E., Addington, A. M., Pierce, S. B., Cooper, G. M., Nord, A. S., Kusenda, M., Malhotra, D., Bhandari, A., et al. (2008) · Science · doi:10.1126/science.1155174 · Cited by 1,800
Common variants conferring risk of schizophrenia
†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
Working memory dysfunction in schizophrenia
(1994) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.6.4.348 · Cited by 1,068
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Cited by
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
Hayashi-Takagi, A., Araki, Y., Nakamura, M., Vollrath, B., Duron, S. G., Yan, Z., Kasai, H., Huganir, R. L., Campbell, D. A., & Sawa, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321109111 · Cited by 101
The muscarinic system, cognition and schizophrenia
Carruthers, S. P., Gurvich, C. T., & Rossell, S. L. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.011 · Cited by 90
Metadata
- Authors
- Ibrahim, H. M., & Tamminga, C. A.
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2011-02-10
- Volume
- 51
- Issue
- 1
- Pages
- 189-209
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2156667276
- Cited by
- 64
- References
- 28
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Schizophrenia: Treatment Targets Beyond Monoamine Systems. https://app.cochat.ai/papers/10.1146/annurev.pharmtox.010909.105851
- The paper
- Ibrahim, H. M., & Tamminga, C. A. (2011). Schizophrenia: Treatment Targets Beyond Monoamine Systems. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev.pharmtox.010909.105851
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.